How Nemifitide diTFA can Save You Time, Stress, and Money.
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge a number of intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Major demo objectives have been To guage the security and tolerability of sifalimumab in dermatomyositis or polym